Autism spectrum disorder (ASD) is a developmental disorder, characterized by deficits in communication, social interactions and sensory perception and by repetitive behavior, typically manifesting in the first three years of life. No curative therapies are available to treat the condition, whose causes remain poorly understood.

In the research article “Therapeutic properties of mesenchymal stem cells for autism spectrum disorders” published in Medical Hypotheses, Dr. Beni Gesundheit, Founder, CEO and Lead Scientist of Cell-El compares the two approaches to stem cell therapy.

In Israeli news and media outlets, Ms. Hanna Abramovich of Israel has shared the amazing progress in her son Avi. Avi presents with ASD. A number of years ago he underwent stem cell therapy. She chose the option of autologous stem cells  from the child’s own stored umbilical cord blood.

Overview of the Cell-El Stem Cell Therapy Blog Series Cell-El studies stem cell therapy as a possible treatment for immune dysfunction. We have been observing

Cell El Ltd. is happy to announce that we are now recruiting infant siblings of children diagnosed with ASD and their mothers for our diagnostic research of ASD biomarkers. The infants (age 10-18 months) have an older sibling diagnosed with ASD and therefore are considered high risk for developing ASD as well. 

Cell-El is soaring forward with the development of an objective diagnostic tool for ASD. The tool will enable early detection of ASD with greater certainty and ease than methods currently used. One mother shared with us her frustrating experience with the uncertainty produced by the current means of diagnosis.

Cell-El’s research focused on a comparison between the levels of 1,000 inflammatory/ immune-related biomarkers in the blood of about 100 children diagnosed with ASD compared to 100 neuro-typically developing (TD) children. We arrived at 85% accuracy in using these biomarkers to differentiate between the ASD and TD children.